Texas Permanent School Fund Corp decreased its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 20.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,753 shares of the biopharmaceutical company’s stock after selling 7,699 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Incyte were worth $1,864,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of INCY. Norges Bank bought a new position in Incyte during the 4th quarter worth approximately $123,253,000. KBC Group NV boosted its stake in Incyte by 842.2% during the 4th quarter. KBC Group NV now owns 955,749 shares of the biopharmaceutical company’s stock worth $60,011,000 after acquiring an additional 854,311 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Incyte by 28.0% during the 2nd quarter. Acadian Asset Management LLC now owns 3,560,989 shares of the biopharmaceutical company’s stock worth $215,833,000 after acquiring an additional 779,243 shares during the last quarter. Swedbank AB bought a new position in Incyte during the 1st quarter worth approximately $37,440,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Incyte by 122.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 892,710 shares of the biopharmaceutical company’s stock worth $54,116,000 after acquiring an additional 490,680 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.
Insider Buying and Selling
In related news, EVP Barry P. Flannelly sold 8,148 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $60.00, for a total transaction of $488,880.00. Following the transaction, the executive vice president now directly owns 50,534 shares in the company, valued at $3,032,040. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, EVP Barry P. Flannelly sold 8,148 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $60.00, for a total transaction of $488,880.00. Following the transaction, the executive vice president now directly owns 50,534 shares in the company, valued at $3,032,040. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Thomas Tray sold 572 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.94, for a total transaction of $36,001.68. Following the transaction, the insider now owns 24,825 shares in the company, valued at $1,562,485.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,047 shares of company stock worth $2,225,626. Insiders own 17.50% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Stock Report on INCY
Incyte Stock Performance
Shares of INCY stock opened at $65.17 on Thursday. The company’s fifty day simple moving average is $64.23 and its 200-day simple moving average is $59.70. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. The firm has a market cap of $14.63 billion, a PE ratio of 19.75, a P/E/G ratio of 5.03 and a beta of 0.73. Incyte Co. has a 12 month low of $50.27 and a 12 month high of $70.36.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.01 billion. Incyte had a return on equity of 0.75% and a net margin of 2.52%. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 EPS. Equities research analysts expect that Incyte Co. will post 0.67 EPS for the current fiscal year.
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
See Also
- Five stocks we like better than Incyte
- Investing in Commodities: What Are They? How to Invest in Them
- How Much Can You Make in Stocks in One Month?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- This Is the Top Large-Cap Stock Insiders Are Buying
- How Investors Can Find the Best Cheap Dividend Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.